Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Aptevo Therapeutics Inc. (APVO)

3.33   0.08 (2.46%) 12-07 19:43
Open: 3.3 Pre. Close: 3.25
High: 3.4 Low: 3.2712
Volume: 27,366 Market Cap: 17(M)

Technical analysis

as of: 2022-12-07 4:20:21 PM
Overall:       
Stoxline posted a BUY today, same as yesterday. Upward movement continues.
Target: Six months: 3.97     One year: 4.63
Support: Support1: 3    Support2: 2.75
Resistance: Resistance1: 3.4    Resistance2: 3.97
Pivot: 3.06
Moving Average: MA(5): 3.18     MA(20): 3.06
MA(100): 3.41     MA(250): 4.55
MACD: MACD(12,26): 0     Signal(9): 0
Stochastic oscillator: %K(14,3): 71.5     %D(3): 61.2
RSI: RSI(14): 62.5
52-week: High: 8.55  Low: 2.67
Average Vol(K): 3-Month: 31 (K)  10-Days: 24 (K)

Price, moving averages and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.
[ APVO ] has closed above the upper band by 1.8%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 26.8% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 3.4 - 3.41 3.41 - 3.42
Low: 3.24 - 3.25 3.25 - 3.27
Close: 3.31 - 3.33 3.33 - 3.35

Company Description

Aptevo Therapeutics Inc., a clinical-stage biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. Its lead clinical candidate is APVO436, a bispecific T-cell engaging antibody candidate that is in Phase 1b clinical trial for acute myelogenous leukemia and myelodysplastic syndrome. The company's preclinical candidates also include ALG.APV-527, an investigational bispecific ADAPTIR candidate that features a mechanism of action to target 4-1BB (CD137) and 5T4, a tumor antigen expressed in various types of cancers; and APVO603, a dual agonist bispecific antibody to target 4-1BB and OX40. It also develoes APVO442, a bispecific candidate based on the ADAPTIR-FLEX platform technology to enhance biodistribution of drugs to PSMA positive tumors for treatment of prostate cancer. The company has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.

Headline News

Thu, 01 Dec 2022
AMGEN PRESENTS NEW AMG 133 PHASE 1 CLINICAL DATA AT WCIRDC 2022 - Investing News Network

Thu, 10 Nov 2022
Aptevo Therapeutics Misses Q3 EPS by 15c By Investing.com - Investing.com UK

Thu, 10 Nov 2022
Aptevo Therapeutics GAAP EPS of -$1.50 beats by $0.14 (NASDAQ:APVO) - Seeking Alpha

Wed, 09 Nov 2022
Alligator Bioscience & Aptevo Therapeutics Announce Publication Highlighting ALG.APV-527 Preclinical Data in Peer-Reviewed Journal Molecular Cancer Therapeutics - Yahoo Finance

Mon, 19 Sep 2022
Alligator Bioscience and Aptevo Therapeutics Announce that FDA has Issued a "May Proceed" Notification for the ALG.APV-527 IND - BioSpace

Thu, 09 Jun 2022
Aptevo Therapeutics Announces New Preliminary Remission Data on Four Additional Patients Enrolled in On-going APVO436 Dose Expansion Phase 1b Trial for the Treatment of Acute Myeloid Leukemia - BioSpace

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Neutral
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 5 (M)
Shares Float 5 (M)
% Held by Insiders 1.1 (%)
% Held by Institutions 17.4 (%)
Shares Short 61 (K)
Shares Short P.Month 53 (K)

Stock Financials

EPS 1.1
EPS Est Next Qtl 2.25
EPS Est This Year 0.58
EPS Est Next Year -2.7
Book Value (p.s.) 3.09
Profit Margin (%) 94.3
Operating Margin (%) -368.8
Return on Assets (ttm) -32.7
Return on Equity (ttm) 48.4
Qtrly Rev. Growth 0
Gross Profit (p.s.) 2.41
Sales Per Share 1.33
EBITDA (p.s.) -4.72
Qtrly Earnings Growth 0
Operating Cash Flow -19 (M)
Levered Free Cash Flow -22 (M)

Stock Valuations

PE Ratio 3.02
PEG Ratio 0
Price to Book value 1.07
Price to Sales 2.49
Price to Cash Flow -0.9

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date 2020-03-26
Ex-Dividend Date Invalid DateTime.
Your Ad Here
android_stock_chart
StockChart iOS
stoxline_lite
StoxlineLite iOS
stoxline_pro
StoxlineLite iOS
Option_Calculator
OptionCalc iOS
android_stock_chart
StockChart Android
stoxline_lite
StoxlineLite Android
stoxline_pro
StoxlinePro Android
Option_Calculator
OptionCalc Android
(c) 2006-2022 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.